These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22028492)

  • 21. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors.
    Fury MG; Sherman E; Haque S; Korte S; Lisa D; Shen R; Wu N; Pfister D
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):591-8. PubMed ID: 21913034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.
    Weide B; Eigentler TK; Pflugfelder A; Zelba H; Martens A; Pawelec G; Giovannoni L; Ruffini PA; Elia G; Neri D; Gutzmer R; Becker JC; Garbe C
    Cancer Immunol Res; 2014 Jul; 2(7):668-78. PubMed ID: 24906352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
    O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
    Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
    Weide B; Eigentler T; Catania C; Ascierto PA; Cascinu S; Becker JC; Hauschild A; Romanini A; Danielli R; Dummer R; Trefzer U; Elia G; Neri D; Garbe C
    Cancer Immunol Immunother; 2019 Sep; 68(9):1547-1559. PubMed ID: 31482307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.
    Catania C; Maur M; Berardi R; Rocca A; Giacomo AM; Spitaleri G; Masini C; Pierantoni C; González-Iglesias R; Zigon G; Tasciotti A; Giovannoni L; Lovato V; Elia G; Menssen HD; Neri D; Cascinu S; Conte PF; Braud Fd
    Cell Adh Migr; 2015; 9(1-2):14-21. PubMed ID: 25562532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
    Danielli R; Patuzzo R; Di Giacomo AM; Gallino G; Maurichi A; Di Florio A; Cutaia O; Lazzeri A; Fazio C; Miracco C; Giovannoni L; Elia G; Neri D; Maio M; Santinami M
    Cancer Immunol Immunother; 2015 Aug; 64(8):999-1009. PubMed ID: 25971540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
    Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
    Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
    Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
    BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Infante JR; Spigel DR; Peyton JD; Thompson DS; Lane CM; Clark BL; Rubin MS; Trent DF; Burris HA
    Cancer; 2010 Sep; 116(17):4122-9. PubMed ID: 20564157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
    Schwager K; Hemmerle T; Aebischer D; Neri D
    J Invest Dermatol; 2013 Mar; 133(3):751-758. PubMed ID: 23096716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
    Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
    Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
    Stoter G; Aamdal S; Rodenhuis S; Cleton FJ; Iacobelli S; Franks CR; Oskam R; Shiloni E
    J Clin Oncol; 1991 Sep; 9(9):1687-91. PubMed ID: 1875225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.
    Pretto F; Elia G; Castioni N; Neri D
    Cancer Immunol Immunother; 2014 Sep; 63(9):901-10. PubMed ID: 24893857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemosensitisation of malignant melanoma by BCL2 antisense therapy.
    Jansen B; Wacheck V; Heere-Ress E; Schlagbauer-Wadl H; Hoeller C; Lucas T; Hoermann M; Hollenstein U; Wolff K; Pehamberger H
    Lancet; 2000 Nov; 356(9243):1728-33. PubMed ID: 11095261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
    Kirkwood JM; Gonzalez R; Reintgen D; Clingan PR; McWilliams RR; de Alwis DP; Zimmermann A; Brown MP; Ilaria RL; Millward MJ
    Cancer; 2011 Oct; 117(20):4732-9. PubMed ID: 21456002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.